BenevolentAI

Ingest relevant scientific literature and genomic data into the knowledge graph.

Apply machine learning models to identify potential drug targets based on disease pathways.

Prioritize targets based on predicted efficacy and safety profiles.

Validate targets using in vitro and in vivo experiments.

Analyze the knowledge graph to identify drugs that interact with key viral proteins.

Predict the efficacy of potential drug candidates using machine learning models.

Validate the efficacy of repurposed drugs in clinical trials.

Train machine learning models on multi-omics data from cancer patients treated with immunotherapy.

Identify potential biomarkers that are correlated with treatment response.

Validate the biomarkers in independent patient cohorts.

Analyze drug-target interactions and off-target effects using the knowledge graph.

Predict potential adverse drug reactions based on known drug safety profiles.

Prioritize high-risk drug candidates for further evaluation.

Analyze patient-specific data (genomics, medical history) to predict treatment response.

Identify optimal therapeutic strategies based on individual patient profiles.

Monitor patient response to therapy and adjust treatment accordingly.

Integrate all available data on the rare disease into the knowledge graph, including scientific literature, patient registries, and genetic databases.

Use machine learning to identify potential therapeutic targets and repurposing opportunities.

Collaborate with researchers and patient advocacy groups to validate findings and advance research.

The system should support multi-omics data.